Eluding Public Scrutiny, Nelfinavir Becomes the Fourth Protease Inhibitor to Hit the Pharmacy Shelves Resistance enigma The US Food & Drug Administration (FDA), which will soon be under the control of Acting Commissioner Dr. Michael Friedman when Commissioner Dr. David…
"Very effective" therapies for: Pneumocystis pneumonia (PCP) tuberculosis (TB) cryptococcosis histoplasmosis "Effective, but toxic" therapies for: toxoplasmic encephalitis "Moderately effective" therapies for: Mycobacterium avium complex (MAC) cytomegalovirus (CMV) "No active treatments" for: cryptosporidiosis/microsporidiosis progressive multifocal leukoencephalopathy (PML)
Opportunistic Infections Continue to Vex the Lives of PWAs as Long As Immunodeficiency Remains 'Postponing the inevitable' Michael Marco and his TAG colleagues working within TAG's Opportunistic Infections Committee (Theo Smart, Laura Morrison, Tim Horn, Paul Dietz, Mark Harrington) released…
Nearly Everyone Agrees On the Need for 'Strategy' Type Clinical Studies -- And That's Where Consensus Ends An intrepid Dr. Lange scales Mt. Sinai First there was the CPCRA's "Moving Target" protocol, which entailed half a decade of arduous, dog-chasing-its-tail…
Activist Epistler Chronicles Frightening Tales of Multiply Resistant HIV from D.C. Principles Panel Toxic cocktail The NIH panel convened late last November to develop new state-of-the-art guidelines for the treatment of HIV infection included a series of provocative (some would…
Dutch Research Team Challenges Ho/Shaw Pathogenetic HIV Model and Gives Cause for Pause Telomeres' fifteeen minutes As long ago as 1995, when the back-to-back Ho and Shaw viral dynamics papers were published, HIV disease has been likened to a colossal…
Resistance and cross-resistance among protease inhibitors Resistant to: Cross-resistance profile SQV 10/12 patients with L90M + 48 had complete or partial loss of sensitivity to other protease inhibitors. RTV Most or all RTV-resistant isolates are resistant to IDV and NFV.…
Four in Favor, Four Against; Long-Awaited Non-Nuke Receives Mixed Reviews at Agency Hearing Clinical benefit elusive In a November 22nd FDA hearing that harkened back to the bad old days of ddC, the Food and Drug Administration's Antiviral Drugs Advisory…
At NIH-Sponsored 'Principles' Panel, A First Peek at Second Phase Decay Data -- and at Lymphoid Architecture FDCs as storage depots In mid-November, an NIH panel convened under the auspices of the Office of AIDS Research (OAR) to discuss scientific…
"It's the Faucet, Stupid." Comparing something called telomere lengths of CD4+ and CD8+ T lymphocytes in HIV-infected and uninfected persons, Amsterdam's Frank Miedema et al. claim "there is no evidence for increased turnover of CD4+ T cells in HIV infection."…